Tscan Accounts Payable from 2010 to 2025

TCRX Stock  USD 1.45  0.15  9.38%   
Tscan Therapeutics Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable will likely drop to about 2.8 M in 2025. Accounts Payable is the amount Tscan Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Tscan Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2010-12-31
Previous Quarter
4.3 M
Current Value
2.8 M
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 8.8 M, Interest Income of 12.7 M or Depreciation And Amortization of 3.6 M, as well as many indicators such as Price To Sales Ratio of 86.63, Dividend Yield of 0.0 or PTB Ratio of 1.48. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tscan Therapeutics Correlation against competitors.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Latest Tscan Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Tscan Therapeutics over the last few years. An accounting item on the balance sheet that represents Tscan Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Tscan Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Tscan Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tscan Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Tscan Accounts Payable Regression Statistics

Arithmetic Mean1,695,916
Geometric Mean1,468,767
Coefficient Of Variation60.90
Mean Deviation857,395
Median1,010,000
Standard Deviation1,032,757
Sample Variance1.1T
Range3.3M
R-Value0.79
Mean Square Error433.9B
R-Squared0.62
Significance0.0003
Slope170,847
Total Sum of Squares16T

Tscan Accounts Payable History

20252.8 M
20244.3 M
20232.4 M
20222.9 M
20211.8 M
20202.9 M

About Tscan Therapeutics Financial Statements

Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable4.3 M2.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.